Program to reduce unnecessary medications for patients with chronic kidney disease
Official title: Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar: A Randomized Controlled Trial
Run by Hamad Medical Corporation · NCT06324045 · Data updated 2026-11-12
This study is testing a program that helps people with chronic kidney disease in Qatar reduce unnecessary medications to see if it improves their health and quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 424 (estimated) |
| Sponsor | Hamad Medical Corporation Industry-sponsored |
| Locations | 1 site (Doha) |
| Status | Recruiting |
| Started | February 19, 2024 |
| Main results expected | December 2025 |
| Study ends | March 2026 |
| Registry record updated | October 1, 2025 |
| Trial ID | NCT06324045 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this program are patients diagnosed with end-stage renal disease receiving hemodialysis or pre-dialysis patients followed at a low clearance clinic in Qatar.
✕Probably not a fit
Patients who are critically ill, have psychiatric conditions, or a limited life expectancy of less than six months may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program aims to address the issue of polypharmacy among patients with chronic kidney disease (CKD) in Qatar by implementing a multidisciplinary deprescribing intervention. The approach involves systematically stopping or adjusting medications to improve clinical outcomes and reduce treatment burden. The study will evaluate the effectiveness of this intervention on patient health and quality of life, while also conducting a cost-benefit analysis to assess its economic viability for healthcare systems. By focusing on a collaborative approach, the program seeks to provide strong evidence for the benefits of deprescribing in CKD management.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life and clinical outcomes for patients with chronic kidney disease by reducing medication burden.
How similar studies have gone: Previous deprescribing initiatives have shown promise in managing polypharmacy in chronic conditions, but this specific multidisciplinary approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients who are: * diagnosed with ESRD receiving hemodialysis treatment or pre-dialysis patients who are followed up at a low clearance clinic. * receiving treatment at one of the ambulatory kidney centers in Qatar for at least two months. * able to communicate in Arabic and/or English. Exclusion Criteria: * Unstable or has a psychiatric condition. * Presents with uncontrolled behaviors or exit-seeking behaviors (i.e., seeking to leave the premises out of confusion, frustration, or anger). * Critically ill patients, pregnant women, children, mentally ill, dementia, and unconscious patients. * Patients with limited life expectancy (less than 6 months).
Where it's running
-
Hamad Medical Corporation
Doha, Qatar Recruiting
Study contacts
- Study coordinator: Abdullah Hamad, MD
- Email: Ahamad9@hamad.qa
- Phone: +97444394888
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Impact of TAVR on kidney function in people with aortic valve disease
This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.
-
Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs
This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
-
Eye-brain-kidney connections in chronic kidney disease
This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.
-
Screening for chronic kidney disease
We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.